Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON

Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON

Objective We assessed adverse events and changes in forced vital capacity (FVC) in patients treated with open-label nintedanib over 148 weeks of SENSCIS-ON, the extension of the SENSCIS trial.Methods Adverse events and changes in FVC over 148 weeks of SENSCIS-ON were assessed in patients who receive...

Full description

Saved in:
Bibliographic Details
Main Authors: Yannick Allanore, Dinesh Khanna, Oliver Distler, Maureen D Mayes, Madelon C Vonk, Kristin B Highland, Arata Azuma, Veronika Kohlbrenner, Margarida Alves, Alexandra James
Format: Article
Language:English
Published: BMJ Publishing Group 2025-02-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/11/1/e005086.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items